Here are 1-3 brief analogies for FibroBiologics (FBLG):

1. Moderna for fibroblast cell therapies. (Like Moderna pioneered mRNA as a novel platform for various treatments, FibroBiologics is pioneering fibroblasts as a novel cell therapy platform for regenerative medicine.)
2. CRISPR Therapeutics, but focused on regenerative fibroblasts instead of gene editing. (Similar to how CRISPR Therapeutics is an innovative, clinical-stage company built around a specific cutting-edge biological platform, FibroBiologics is developing a platform based on fibroblasts for tissue regeneration.)
3. Like a Mesoblast (stem cell therapy company), but using fibroblasts because they see them as a superior alternative to stem cells for regeneration. (Mesoblast is known for allogeneic stem cell therapies; FibroBiologics is also in regenerative cell therapy but specifically highlights fibroblasts as a more advantageous cell type.)

• Fibroblast-based therapies for Degenerative Disc Disease: Clinical-stage cell therapy designed to regenerate tissue in patients suffering from degenerative disc disease.
• Fibroblast-based therapies for Multiple Sclerosis: Clinical-stage cell therapy aimed at addressing multiple sclerosis.
• Fibroblast-based therapies for Wound Healing: Clinical-stage cell therapy intended to facilitate the healing of wounds.
• Fibroblast-based therapies for Certain Cancers: Clinical-stage cell therapy under development for the treatment of specific cancers.
• Fibroblast-based therapies for Thymic and Splenic Involution Reversal: Clinical-stage cell therapy focused on potential extension of life applications by reversing the involution of the thymus and spleen.

FibroBiologics (FBLG) is a clinical-stage cell therapy company. The provided background information indicates that the company is currently focused on developing and commercializing fibroblast-based therapies and that "no fibroblast therapy products have been approved" to date. Their commercial sales are contingent on future marketing approval.

Therefore, FibroBiologics currently does not have major customers, as their product candidates are still in the development and clinical trial stages and have not yet received marketing approval for commercial sale.

Pete O'Heeron, Chief Executive Officer and Chairman

Pete O'Heeron is the Founder and Chief Executive Officer of FibroBiologics, having over 25 years of experience in medical technology and biotech development. He holds more than 350 patents issued and pending in biologics, cell therapy, and medical devices. O'Heeron founded Advanced Medical Technologies, an operational investment group, and NeoSurg Technologies, which developed the T2000 Minimally Invasive Access System and was subsequently sold to Cooper Surgical in 2006. He also has executive-level experience from Christus Health Care Corporation and completed an Executive Program in Mergers and Acquisitions at the University of Chicago.

Jason D. Davis, Chief Financial Officer

Jason D. Davis was appointed Chief Financial Officer of FibroBiologics in June 2025, bringing over 20 years of experience in public company and capital markets. He previously served as CFO at Virax Biolabs, where he led their successful IPO in 2022. Davis also held the CFO position at HyperDynamics Corp, contributing to a significant increase in market capitalization and raising over $200 million. His expertise encompasses corporate finance, capital markets, and SEC reporting.

Hamid Khoja, Ph.D., Chief Scientific Officer

Hamid Khoja serves as the Chief Scientific Officer of FibroBiologics.

Ruben Garcia, General Counsel

Ruben Garcia was appointed General Counsel of FibroBiologics in March 2024, bringing over 20 years of legal leadership experience in the pharmaceutical industry. He previously served as Senior Vice President, General Counsel, and Corporate Secretary at AcelRx Pharmaceuticals, Inc., and Senior Corporate Counsel and Assistant Secretary for Ultragenyx Pharmaceutical Inc. Garcia began his legal career at Vinson & Elkins L.L.P. and Jones Day.

Here are the key risks to FibroBiologics' business:

1. Regulatory Approval and Market Acceptance Risk: FibroBiologics operates in a novel and evolving field where, to date, no fibroblast therapy products have received regulatory approval. The regulatory landscape for cell therapy is rigorous, complex, and uncertain, meaning the company cannot predict the time and cost of obtaining approval, or if it will receive it at all, for any of its product candidates. The success of their entire business model hinges on demonstrating the safety and efficacy of their fibroblast-based therapies to gain regulatory approval and subsequent market acceptance.
2. Significant Development, Manufacturing, and Commercialization Costs and Financial Health: As a clinical-stage biotechnology company with no current revenue, FibroBiologics faces substantial and potentially escalating costs for research and development, manufacturing, and commercialization of its product candidates. The company has reported ongoing net losses and significant operational challenges, with current cash and cash equivalents indicating the continuous need to secure capital to fund its operations and advance its clinical trials. There is a risk that actual costs could exceed estimates, impacting the company's liquidity and ability to sustain its business.
3. Intense Competition, Rapid Technological Advancement, and Clinical Trial Risks: The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies and intense competition. FibroBiologics' product candidates will compete with existing therapies and new therapies that may emerge. Furthermore, the company has limited experience in designing clinical trials and faces inherent risks associated with preclinical and clinical development, including unexpected delays, difficulties in obtaining regulatory approval, or failure of product candidates at any stage due to safety or efficacy issues. The unpredictable relationship between preclinical and clinical trial results also poses a significant risk to the successful progression of their therapies.

FibroBiologics (FBLG) targets several significant addressable markets for its fibroblast-based therapies:

• Degenerative Disc Disease: The global degenerative disc disease treatment market was valued at approximately $28 billion in 2022 and is projected to reach $46.2 billion by 2032. Another estimate places the global market at $34.0 billion in 2024, expected to grow to $66.2 billion by 2033. North America held a substantial share, with the U.S. market projected to be $10.8 billion in 2024 and growing to $20.3 billion by 2033.
• Multiple Sclerosis: The global multiple sclerosis (MS) drug market was approximately $21.3 billion in 2023 and is projected to reach approximately $38.9 billion globally by 2032. North America represented about 48% of this market. Another report indicates the multiple sclerosis disease-modifying therapy market across the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) is expected to grow from $22.0 billion in 2024 to $25.9 billion in 2034, with the U.S. market alone estimated at $15.7 billion in 2024.
• Wound Healing: The global wound care market was valued at approximately $21.0 billion in 2024 and is projected to grow to $35.9 billion by 2032. Specifically for burn care, the worldwide market is estimated at $2.55 billion, growing to $3.35 billion by 2030. The overall global wound care market was estimated at $24.9 billion in 2024 and is expected to reach $44.2 billion by 2034. The U.S. wound care market is projected to reach $11.9 billion by 2034.
• Certain Cancers (specifically Cachexia): The cancer cachexia market is projected to reach $3.2 billion globally by 2032. More broadly, the global cancer therapy market size was $269.55 billion in 2026 and is forecast to reach $446.89 billion by 2031.
• Potential Extension of Life Applications (Human Longevity): The global Longevity and Anti-senescence Therapy market was estimated at $27.15 billion in 2024 and is projected to grow to $42.19 billion by 2031. North America held over 40% of the global revenue in 2024. Another report suggests the global longevity therapeutics market is projected to reach $43.72 billion by 2033, growing from $23.24 billion in 2024.

For FibroBiologics (FBLG), a clinical-stage cell therapy company, the expected drivers of future revenue growth over the next 2-3 years are centered on advancing its pipeline through clinical development and strengthening its market position, rather than immediate product sales, as analysts currently project no revenue for the company through 2028. The key drivers include:

1. Successful Advancement of Lead Product Candidates Through Clinical Trials: The primary driver of future revenue potential for FibroBiologics is the positive progression and outcomes from its ongoing and planned clinical trials. The company is currently engaged in a Phase 1/2 clinical trial for CYWC628 for the treatment of diabetic foot ulcers (DFU) in Australia, with site onboarding completed in March 2026 and interim results expected in the first half of 2026, and final results by the end of 2026. Additionally, FibroBiologics has submitted an Investigational New Drug (IND) application for CYPS317 for psoriasis and aims for IND approval in 2026 for its multiple sclerosis (CYMS101) and degenerative disc disease (CybroCell™) programs. Positive data from these trials are crucial for moving closer to regulatory approval and eventual commercialization.

2. Expansion and Strengthening of Intellectual Property Portfolio: FibroBiologics holds an extensive intellectual property portfolio with over 270 issued and pending patents across various clinical pathways. Continuous expansion of this portfolio, as evidenced by recent U.S. patents for osteoporosis treatment in March 2026 and cachexia in February 2026, provides a competitive advantage and is fundamental to attracting partnerships and ensuring market exclusivity for future products.

3. Securing Strategic Partnerships and Additional Funding: As a clinical-stage biotechnology company with significant research and development expenses, securing further strategic collaborations and funding is vital. FibroBiologics has already partnered with Charles River Laboratories for the development and manufacturing of its fibroblast-based spheroids product, CYWC628, for its DFU clinical trial. Continued success in attracting additional investment, such as the $7.2 million raised through direct offerings in late 2025 and a $25 million financing plan, is essential to fuel ongoing clinical development and prepare for commercialization.

4. Progression of Pre-clinical Programs into Clinical Development: Diversifying its pipeline by advancing promising pre-clinical programs into human clinical trials will broaden FibroBiologics' future revenue streams. The company announced advances in burn treatment using its fibroblast spheroid technology in March 2026, with plans to move towards clinical development. Additionally, significant advancements in its Bone Marrow Organoid platform, with potential for hematopoietic cancers and age-related immune decline, were reported in September 2025, indicating future pipeline expansion. These advancements increase the potential for a wider range of commercialized therapies in the long term.

Share Issuance

• In December 2025, FibroBiologics entered into agreements for a registered direct offering to issue 5.23 million shares of common stock at $0.33 per share, expected to generate approximately $1.7 million in gross proceeds. Concurrently, unregistered warrants for an equal number of shares were issued, potentially raising an additional $1.7 million upon full exercise.
• The company reported raising a total of $7.2 million through multiple direct offerings in 2025.
• In November 2025, FibroBiologics completed a registered direct offering to an existing shareholder for approximately $4 million, involving the issuance of common stock and pre-funded warrants, with the purchase price paid in sovereign-issued gold coins.

Inbound Investments

• In December 2024, FibroBiologics entered into a Standby Equity Purchase Agreement with YA II PN LTD. (Yorkville), an investment fund, which allows the company to sell up to $25 million of its common stock over two years. The initial $15 million was advanced in three equal tranches of convertible promissory notes, with the first $5 million funded upon agreement.
• FibroBiologics secured $4 million in new investment capital from investors in November 2025, paid in gold coins, intended to accelerate research and development initiatives.
• In February 2023, FibroBiologics achieved the highest amount raised per biotech investor in StartEngine.com history through an equity crowdfunding offering.

Capital Expenditures

• Research and development expenses for the year ended December 31, 2025, were approximately $7.4 million, an increase from $4.5 million in 2024. This rise was primarily due to increased contract research organization (CRO) costs for clinical trial preparation, lab facilities expenses, additional personnel, and depreciation for laboratory equipment.
• For the nine months ended September 30, 2025, research and development expenses were approximately $6.6 million, up from $3.1 million in the same period in 2024, driven by increased contract research and CRO costs, lab facilities, personnel, and research materials.
• The net proceeds from the $25 million financing secured in December 2024 are expected to fund research and development programs and support upcoming clinical trials, including the Phase 1/2 diabetic foot ulcer trial.